Today, LifePlan Financial Group Inc invests in Pfizer Inc. (PFE) Shares

Today, LifePlan Financial Group Inc invests in Pfizer Inc. (PFE) Shares
LifePlan Financial Group Inc raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,125 shares of the biopharmaceutical company’s stock after buying an additional 311 shares during the period. LifePlan Financial Group Inc’s holdings in Pfizer were worth $445,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in PFE. Ronna Sue Cohen boosted its stake in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares in the last quarter. Delphi Private Advisors LLC boosted its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares in the last quarter. Acadia Trust NA boosted its stake in shares of Pfizer by 0.5% in the second quarter. Acadia Trust NA now owns 14,032 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 67 shares in the last quarter. New England Private Wealth Advisors LLC boosted its stake in shares of Pfizer by 0.4% in the second quarter. New England Private Wealth Advisors LLC now owns 18,135 shares of the biopharmaceutical company’s stock valued at $639,000 after buying an additional 77 shares in the last quarter. Finally, Darrell & King LLC boosted its stake in shares of Pfizer by 0.5% in the second quarter. Darrell & King LLC now owns 17,550 shares of the biopharmaceutical company’s stock valued at $567,000 after buying an additional 81 shares in the last quarter. 69.48% of the stock is owned by institutional investors.

Shares of Pfizer Inc. (NYSE:PFE) traded up 0.86% on Friday, reaching $31.69. 10,452,948 shares of the company’s stock traded hands. The stock has a market capitalization of $192.31 billion, a PE ratio of 31.82 and a beta of 0.90. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The company has a 50 day moving average of $32.01 and a 200-day moving average of $34.15.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by $0.01. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The business had revenue of $13.05 billion for the quarter, compared to analysts’ expectations of $13.05 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Pfizer’s quarterly revenue was up 7.9% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post $2.41 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.79%. Pfizer’s dividend payout ratio is currently 106.20%.

Several brokerages recently issued reports on PFE. Argus reaffirmed a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research note on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research note on Monday, September 26th. Citigroup Inc. reissued a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a research note on Wednesday, August 3rd. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target for the company in a research note on Tuesday, August 2nd. Finally, Jefferies Group set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 1st. Thirteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Pfizer presently has a consensus rating of “Buy” and an average target price of $37.73.

In other news, insider Anthony J. Maddaluna sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total value of $330,000.00. Following the completion of the transaction, the insider now directly owns 112,087 shares in the company, valued at $3,698,871. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $30.05, for a total transaction of $552,619.50. Following the completion of the transaction, the insider now owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. Company insiders own 0.07% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment